Identity
HGNC
LOCATION
11q23.3
LOCUSID
ALIAS
Epoc-1,OCT-11,OCT11,OTF-11,PLA-1,PLA1,Skn-1a
FUSION GENES
Non-annotated gene. Preliminary data : if you are an author who wish to write a full paper/card on this gene, contribute in submission tool
Other Information
Locus ID:
NCBI: 25833
MIM: 607394
HGNC: 19864
Ensembl: ENSG00000137709
Variants:
dbSNP: 25833
ClinVar: 25833
TCGA: ENSG00000137709
COSMIC: POU2F3
RNA/Proteins
| Gene ID | Transcript ID | Uniprot |
|---|---|---|
| ENSG00000137709 | ENST00000260264 | Q9UKI9 |
| ENSG00000137709 | ENST00000532663 | H0YLC5 |
| ENSG00000137709 | ENST00000533620 | E9PIN6 |
| ENSG00000137709 | ENST00000543440 | Q9UKI9 |
Expression (GTEx)
Pathways
| Pathway | Source | External ID |
|---|---|---|
| Herpes simplex infection | KEGG | ko05168 |
| Herpes simplex infection | KEGG | hsa05168 |
Protein levels (Protein atlas)
References
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 37904277 | 2024 | POU2F3-Expressing Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma Show Morphologic and Phenotypic Overlap. | 1 |
| 37904277 | 2024 | POU2F3-Expressing Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma Show Morphologic and Phenotypic Overlap. | 1 |
| 36716535 | 2023 | The predictive value of YAP-1 and POU2F3 for the efficacy of immuno-chemotherapy in extensive-stage SCLC patients. | 0 |
| 36815540 | 2023 | An integrated multiomics analysis of rectal cancer patients identified POU2F3 as a putative druggable target and entinostat as a cytotoxic enhancer of 5-fluorouracil. | 0 |
| 36716535 | 2023 | The predictive value of YAP-1 and POU2F3 for the efficacy of immuno-chemotherapy in extensive-stage SCLC patients. | 0 |
| 36815540 | 2023 | An integrated multiomics analysis of rectal cancer patients identified POU2F3 as a putative druggable target and entinostat as a cytotoxic enhancer of 5-fluorouracil. | 0 |
| 34988657 | 2022 | POU2F3 beyond thymic carcinomas: expression across the spectrum of thymomas hints to medullary differentiation in type A thymoma. | 13 |
| 35576971 | 2022 | OCA-T1 and OCA-T2 are coactivators of POU2F3 in the tuft cell lineage. | 23 |
| 35760287 | 2022 | POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC. | 14 |
| 36197978 | 2022 | POU2AF2/C11orf53 functions as a coactivator of POU2F3 by maintaining chromatin accessibility and enhancer activity. | 18 |
| 34988657 | 2022 | POU2F3 beyond thymic carcinomas: expression across the spectrum of thymomas hints to medullary differentiation in type A thymoma. | 13 |
| 35576971 | 2022 | OCA-T1 and OCA-T2 are coactivators of POU2F3 in the tuft cell lineage. | 23 |
| 35760287 | 2022 | POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC. | 14 |
| 36197978 | 2022 | POU2AF2/C11orf53 functions as a coactivator of POU2F3 by maintaining chromatin accessibility and enhancer activity. | 18 |
| 33011388 | 2020 | SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. | 149 |
Citation
Dessen P
POU2F3 (POU class 2 homeobox 3)
Atlas Genet Cytogenet Oncol Haematol. 2007-02-01
Online version: http://atlasgeneticsoncology.org/gene/43760/pou2f3
